Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-31T23:27:25.053Z Has data issue: false hasContentIssue false
  • English
  • Français

Is schizophrenia an HLA-associated disease?

Published online by Cambridge University Press:  09 July 2009

Peter McGuffin
Peter McGuffin*
Affiliation:
Maudsley Hospital, London
*
1Address for correspondence: Dr Peter McGuffin, The Maudsley Hospital, Denmark Hill, London SE5 8AZ.
Get access Rights & Permissions [Opens in a new window]

Synopsis

Certain specificities of the human leukocyte antigen (HLA) system have been shown to be associated with particular diseases. A review of recent studies in schizophrenia shows inconsistent results for schizophrenia as a whole, although a significant increase in HLA A28 remains on combining the data. There are more consistent findings for disease subtypes. In particular, HLA A9 and HLA CW4 are increased in paranoid schizophrenics, while HLA Al and the A1–B8 haplotype are increased in nuclear forms. It is postulated that the relationship between the schizophrenias and certain HLA types could be due to an influence of the latter upon neuronal postsynaptic membrane sensitivity to central neurotransmitters such as dopamine.

Type
Research Article
Information
Psychological Medicine , Volume 9 , Issue 4 , November 1979 , pp. 721 - 728
Copyright
Copyright © Cambridge University Press 1979

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Bird, E. D., Spokes, E. G., Barnes, J., Mackay, A. V. P., Iversen, L. L. & Shepherd, M. (1977). Increased brain dopamine and reduced GAD. and C.A.T. activity in schizophrenic and related psychoses. Lancet ii, 1157.CrossRefGoogle Scholar
Bodmer, W. F. & Bodmer, D. G. (1974). The HLA histocompatibility antigens and disease. Advanced Medicine Symposium 10, 157–174. Royal College of Physicians of London. Pitman Medical London.Google Scholar
Bowers, M. B. (1974). Central dopamine turnover in schizophrenic syndromes. Archives of General Psychiatry 31, 50–54.CrossRefGoogle ScholarPubMed
Burch, P. R. D. (1964). Schizophrenia: some new aetiological considerations. British Journal of Psychiatry 110, 818–896.CrossRefGoogle ScholarPubMed
Carlsson, A. (1978). Does dopamine have a role in schizophrenia? Biological Psychiatry 13(1), 3–21.Google ScholarPubMed
Castellano, C., Eleftherion, B. E., Bailey, D. W. & Oliverio, A. (1974). Chlorpromazine and avoidance: a genetic analysis. Psychopharmacologia (Berlin) 34, 309–316.CrossRefGoogle ScholarPubMed
Cazzullo, C. L., Smeraldi, E. & Penati, G. (1974). The leukocyte antigen system HLA as a possible genetic marker of schizophrenia. British Journal of Psychiatry 25, 25–27.CrossRefGoogle Scholar
Cooper, J. E., Kendell, R. E., Gurland, B. J., Sharpe, L., Copeland, J. R. M. & Simon, R. (1972). Psychiatric Diagnosis in New York and London. Maudsley Monograph no. 20. Oxford University Press: London.Google Scholar
Crow, T. J. (1977). The role of dopamine in the anti-psychotic affect and pathogenesis of schizophrenia. Proceedings of the Royal Society of Medicine 70, Supplement 10, 15–19.CrossRefGoogle Scholar
Crow, T. J. & Gillbe, C. (1976). Brain dopamine and behaviour. Journal of Psychiatric Research 11, 163–172.CrossRefGoogle Scholar
Crow, T. J., Deakin, J. F. W., Johnstone, E. C. & Longden, A. (1976). Dopamine and schizophrenia. Lancer ii, 563–566.CrossRefGoogle Scholar
Eberhard, G., Franzen, G. & Low, B. (1975). Schizophrenia susceptibility and HLA antigen. Neuropsychobiology 1, 211–217.CrossRefGoogle Scholar
Ferguson, R. M., Schmidtke, J. R. & Simmons, R. L. (1975). Concurrent inhibition by chlorpromazine of coreavalin A induced lymphocyte aggregation and mitogenesis. Nature 256, 744–745.CrossRefGoogle ScholarPubMed
Friedhoff, A. J. (1977). Receptor sensitivity modifications (RSM) – a new paradigm for the potential treatment of some hormonal and transmitter disturbances. Comprehensive Psychiatry 18 (4), 309–317.CrossRefGoogle ScholarPubMed
Galant, S. & Remo, R. (1975). Beta adrenergic inhibition of T lymphocyte rosettes. Journal of Immunology 114, 512–513.CrossRefGoogle ScholarPubMed
Harris, R. (1978). HLA antigens and disease susceptibility. Medicine (3rd series) 2, 92–98.Google Scholar
Heath, R. G. & Krupp, I. M. (1967). Schizophrenia as an immunologic disorder. Archives of General Psychiatry 16, 1–9.CrossRefGoogle ScholarPubMed
Huber, G., Gross, G. & Schutter, R. (1975). Long-term follow-up of schizophrenia: psychiatric course of illness and prognosis. Acta Psychiatrica Scandinavia 52, 49–57.CrossRefGoogle ScholarPubMed
Ivanyi, D., Zemek, P. & Ivanyi, P. (1976). HLA antigens in schizophrenia. Tissue Antigens 8 (3), 217–220.CrossRefGoogle ScholarPubMed
Ivanyi, P. (1978). Some aspects of the H2 system, the major histocompatibility system in the mouse. Proceedings of the Royal Society of London B 202, 117–158.Google ScholarPubMed
Ivanyi, P., Ivanyi, D. & Zemek, P. (1977). HLA–CW4 in paranoid schizophrenia. Tissue Antigens 9, 41–44.CrossRefGoogle ScholarPubMed
Iversen, L. L. (1977). Dopaminergic mechanisms in schizophrenia and their relevance to therapeutics and aetiology. Proceedings of the Royal Society of Medicine 70, Supplement 10, 1–4.CrossRefGoogle Scholar
Joysey, V. C. & Woolf, E. (1978). HLA-A, B and C antigens, their serology and cross reaction. British Medical Bulletin 34 (3), 217–222.CrossRefGoogle Scholar
Julien, R. A., Mercier, P., Chouraqui, P. & Sutter, J. M. (1978). Schizophrenics et antigènes d'histocompatibilité. L'Encéphale 4, 99–113.Google Scholar
Kolyaskina, G. T. & Vartanian, M. F. (1975). The genetic aspects of immunopathogenesis mechanisms in schizophrenia. In Studies in Schizophrenia, pp. 48–53. British Journal of Psychiatry, Special Publication no. 10. Headley Bros.: Ashford.Google Scholar
Lee, T., Seeman, P., Tourtelotte, W. W., Farley, I. S. & Hornykiewicz, O. (1978). Binding of 3H neuroleptics and 5H apomorphine in schizophrenic brains. Nature 274, 897–900.CrossRefGoogle Scholar
McGuffin, p. (1979). The HLA system and schizophrenia in England. Proceedings of the 2nd World Congress of Biological Psychiatry.Elsevier/North Holland Biomedical Press:Amsterdam.Google Scholar
McGuffin, P., Farmer, A. E. & Rajah, S. M. (1978). Histocompatability antigens and schizophrenia. British Journal of Psychiatry 132, 149–151.CrossRefGoogle ScholarPubMed
Mercier, P., Sutter, J. M., Julien, R. A. & Kieffer, N. (1977). Schizophrenie: association de la forme paranoide aux antigenes HLA A et B. L'Encéphale 3, 49–53.Google Scholar
Oliver, R. T. D. (1977). Histocompatibility antigens and human disease. British Journal of Hospital Medicine 11, 449–459.Google Scholar
Owen, F., Crow, T. J., Poulter, M., Cross, A. D., Longden, A. & Riley, G. J. (1978). Increased dopamine receptor sensitivity in schizophrenia. Lancet ii, 223–226.CrossRefGoogle Scholar
Perry, T. L., Kish, S. J., Buchanan, J. & Hansen, S. (1979). Gamma aminobutyric-acid deficiency in brain of schizophrenic patients. Lancet i, 237–239.CrossRefGoogle Scholar
Post, R. M., Fink, E. & Goodwin, F. R. (1975). Cerebrospinal fluid amine metabolites in acute schizophrenia. Archives of General Psychiatry 32, 1063–1069.CrossRefGoogle ScholarPubMed
Schneider, K. (1959). Clinical Psychopathology (trans. Hamilton, M. W.). Grune and Stratton: New York.Google Scholar
Scorza-Smeraldi, R., Smeraldi, E., Fabio, G., Bellodi, L., Sacchetti, E. & Rugarli, C. (1977). Interference between anti HLA antibodies and adrenergic receptor binding drugs. Tissue Antigens 9, 163–166.CrossRefGoogle ScholarPubMed
Smeraldi, E. & Scorza-Smeraldi, R. (1976). Interference between anti HLA antibodies and chlorpromazine. Nature 260, 532–534.CrossRefGoogle ScholarPubMed
Smeraldi, E., Bellodi, L. & Cazzullo, C. L. (1976 a). Further studies on the major histocompatibility complex as a genetic marker for schizophrenia. Biological Psychiatry 11, 655–661.Google ScholarPubMed
Smeraldi, E., Bellodi, L., Sacchetti, E. & Cazzullo, C. L. (1976 b). The HLA system and the clinical response to treatment with chlorpromazine. British Journal of Psychiatry 129, 486–489.CrossRefGoogle ScholarPubMed
Smeraldi, E., Scorza-Smeraldi, R., Fabio, G. – Sacchetti, E. (1976 c). HLA–SD antigens and schizophrenia: statistical and genetical considerations. Tissue Antigens 8, 191–196.CrossRefGoogle ScholarPubMed
Snell, G. B., Dausett, J. & Nathenson, S. (1976). Histocompatibility. Academic Press: London and New York.Google Scholar
Svejgaard, A. (1976). The HLA System: an Introductory Survey. Monographs in Human Genetics No. 7. S. Karger: Basel.Google Scholar
Svejgaard, A. & Ryder, L. P. (1976). Interaction of HLA molecules with non-immunological ligands as an explanation of HLA and disease associations. Lancet ii, 547–549.CrossRefGoogle Scholar
Svejgaard, A., Platz, P., Ryder, L. P., Neilson, L. S. & Thomson, M. (1975). HLA and disease associations — a survey. Transplant Review 22, 3–39.Google ScholarPubMed
Taylor, M. A. (1972). Schneiderian first rank symptoms and clinical prognostic features in schizophrenia. Archives of General Psychiatry 26, 64–67.CrossRefGoogle ScholarPubMed
Terasaki, P. I. & Mickey, M. R. (1975). The HLA haplotypes in 32 diseases. Transplant Review 33, 102–120.Google Scholar
Tsuang, M. T. & Winokur, G. (1974). Criteria for sub-typing schizophrenia. Archives of General Psychiatry 31, 43–47.CrossRefGoogle Scholar
Woolf, B. (1955). On estimating the relation between blood group and disease. Annals of Human Genetics 19, 251–253.CrossRefGoogle ScholarPubMed
World Health Organization (1972). Report of International Pilot Study of Schizophrenia, Vol. 1. WHO: Geneva.Google Scholar